TY - JOUR
T1 - Controlled trial of chlorpromazine as antisecretory agent in patients with cholera hydrated intravenously
AU - Rabbani, G. H.
AU - Greenough, W. B.
AU - Holmgren, J.
AU - Kirkwood, B.
N1 - Funding Information:
This work was jointly supported by the International Centre for Diarrhoeal Disease Research, Bangladesh; SAREC, Sweden; and the Swedish Medical Research Council. Requests for reprints should be addressed to: G H Rabbani, ICDDR, B, GPO Box 128, Dacca-2, Bangladesh.
PY - 1982
Y1 - 1982
N2 - A randomised controlled trial was conducted to investigate the ability of chlorpromazine to reduce intestinal secretion in cholera. Chlorpromazine had reduced loss of intestinal fluid in animals with diarrhoea induced by cholera toxin, and in a preliminary study the drug had reduced purging in patients with cholera. Forty-six adults with cholera were included in the randomised trial. Of these, 34 were treated with chlorpromazine (1 mg/kg or 4 mg/kg either by mouth or intramuscularly) and 12 served as controls. After treatment with the drug there was a significantly greater reduction in the rate of fluid loss in the treated patients than in the controls during the first (p < 0.005), second (p < 0.05), and fourth (p < 0.01) eight-hour periods but not during the third eight-hour period; the dose of 4 mg/kg was only marginally more effective than 1 mg/kg. The effect of chlorpromazine was strikingly biphasic, with one peak during the first eight hours and another 24-32 hours after administration. Chlorpromazine also significantly reduced the duration of diarrhoea, frequency of vomiting, and amount of intravenous fluid required. The drug induced mild sedation and no hypotension in these well-hydrated patients.
AB - A randomised controlled trial was conducted to investigate the ability of chlorpromazine to reduce intestinal secretion in cholera. Chlorpromazine had reduced loss of intestinal fluid in animals with diarrhoea induced by cholera toxin, and in a preliminary study the drug had reduced purging in patients with cholera. Forty-six adults with cholera were included in the randomised trial. Of these, 34 were treated with chlorpromazine (1 mg/kg or 4 mg/kg either by mouth or intramuscularly) and 12 served as controls. After treatment with the drug there was a significantly greater reduction in the rate of fluid loss in the treated patients than in the controls during the first (p < 0.005), second (p < 0.05), and fourth (p < 0.01) eight-hour periods but not during the third eight-hour period; the dose of 4 mg/kg was only marginally more effective than 1 mg/kg. The effect of chlorpromazine was strikingly biphasic, with one peak during the first eight hours and another 24-32 hours after administration. Chlorpromazine also significantly reduced the duration of diarrhoea, frequency of vomiting, and amount of intravenous fluid required. The drug induced mild sedation and no hypotension in these well-hydrated patients.
UR - http://www.scopus.com/inward/record.url?scp=0020036083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0020036083&partnerID=8YFLogxK
U2 - 10.1136/bmj.284.6326.1361
DO - 10.1136/bmj.284.6326.1361
M3 - Article
C2 - 6803977
AN - SCOPUS:0020036083
VL - 284
SP - 1361
EP - 1364
JO - British Medical Journal
JF - British Medical Journal
SN - 0959-8146
IS - 6326
ER -